Pfizer Inc. (NYSE:PFE) Stock Now Rated "Hold" by Sell-Side Analysts

Key Points

• Analyst sentiment is neutral: 21 brokerages rate Pfizer “Hold” on average—13 holds, six buys and two sells—with a mean 12-month price target of $30.39.
• Pfizer beat quarterly expectations, reporting EPS of $0.87 versus $0.74 forecast and revenue of $16.58 billion versus $15.85 billion expected; revenue was down 0.4% year over year.
• The company declared a quarterly dividend of $0.43 per share, equivalent to $1.72 annually and a stated yield of 5.9%.

Shares of Pfizer Inc. (NYSE:PFE - Get Free Report) have been given a consensus rating of "Hold" by the twenty-one brokerages that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and six have given a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $30.39.

A number of brokerages have recently weighed in on PFE. BMO Capital Markets dropped their price target on Pfizer from $34.00 to $30.00 and set an "outperform" rating for the company in a research report on Monday, July 13th. UBS Group boosted their price objective on shares of Pfizer from $27.00 to $30.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 4th. DZ Bank cut shares of Pfizer from a "buy" rating to a "hold" rating in a research note on Friday. Cantor Fitzgerald raised their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Thursday, October 8th. Finally, JPMorgan Chase & Co. raised their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a report on Friday, October 9th.

Pfizer Price Performance

Shares of NYSE:PFE opened at $29.38 on Monday. The business's 50 day simple moving average is $28.74 and its 200-day simple moving average is $26.90. The firm has a market capitalization of $167.47 billion, a price-to-earnings ratio of 41.97, a price-to-earnings-growth ratio of 1.93 and a beta of 0.31. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.42 and a quick ratio of 1.10. Pfizer has a 12 month low of $23.62 and a 12 month high of $31.44.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.13. The firm had revenue of $16.58 billion during the quarter, compared to analysts' expectations of $15.85 billion. Pfizer had a return on equity of 19.88% and a net margin of 6.34%. Pfizer's revenue was down .4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.87 earnings per share. As a group, equities analysts forecast that Pfizer will post 3.04 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be given a $0.43 dividend. The ex-dividend date is Friday, November 6th. This represents a $1.72 annualized dividend and a dividend yield of 5.9%. Pfizer's dividend payout ratio is currently 245.71%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s third-quarter results beat analyst expectations, and the company raised its 2026 earnings outlook. Reports also highlighted momentum from newer products, although margin pressure remains a concern. Pfizer Q3 Earnings Rebuild Confidence As New Drugs Gain Ground
• Positive Sentiment: Guggenheim reiterated a Buy view and raised its price target to $33 from $31, signaling potential upside in the analyst’s view. Pfizer Receives a Buy from Guggenheim
• Neutral Sentiment: Pfizer updated an ulcerative-colitis treatment-pattern study and advanced a Phase 3 RSV-vaccine study in high-risk children. The announcements describe ongoing research; no efficacy or safety results were provided in the summaries. Pfizer Advances Phase 3 RSV Vaccine Study
• Negative Sentiment: DZ Bank cut its rating on Pfizer from Buy to Hold, a less favorable view that may temper optimism from other analysts. Pfizer also lagged in a news report focused on Moderna’s earnings-driven gain, though that comparison is not a change in Pfizer’s fundamentals. DZ Bank recommendations Moderna Climbs as Pfizer Dips

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Retirement Wealth Solutions LLC boosted its holdings in Pfizer by 144.6% during the third quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 509 shares in the last quarter. Keb Asset Management LLC acquired a new position in Pfizer in the second quarter worth approximately $26,000. Field & Main Bank bought a new position in shares of Pfizer in the second quarter valued at $27,000. Bullseye Investment Management LLC bought a new position in shares of Pfizer in the second quarter valued at $28,000. Finally, Timbuktu Capital Management LLC acquired a new stake in shares of Pfizer during the 2nd quarter valued at $29,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

About Pfizer

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.